Pregabalin-associated Elevation of Clozapine Serum Levels

M. Gahr; M. M. Schmid; C. Schönfeldt-Lecuona

doi:10.1055/s-0032-1306312

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2012; 45(07): 297-299
DOI: 10.1055/s-0032-1306312

Letter

Pregabalin-associated Elevation of Clozapine Serum Levels

M. Gahr

¹Department of Psychiatry and Psychotherapy III, University Hospital of Ulm, Ulm University, Ulm, Germany

,

M. M. Schmid

¹Department of Psychiatry and Psychotherapy III, University Hospital of Ulm, Ulm University, Ulm, Germany

,

C. Schönfeldt-Lecuona

¹Department of Psychiatry and Psychotherapy III, University Hospital of Ulm, Ulm University, Ulm, Germany

› Author Affiliations

Abstract

We report our experience with a 34-year-old patient with schizophrenia, paranoid subtype, who demonstrated an elevation of clozapine serum levels subsequent to pregabalin comedication used for the treatment of schizophrenic anxiety. This observation turned to be dose-dependent. Although the pharmacokinetic profile of pregabalin suggests an exclusive renal elimination, our report supports the presumption of a possible direct or indirect hepatic “effect” of pregabalin.

Key words

pharmacokinetics - schizophrenia treatment - antipsychotic drugs - adverse effects - schizophrenia

Full Text

References

References
1 Sills G. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6: 108-113
2 Lanneau C, Green A, Hirst W et al. Gabapentin is not a GABA_B receptor agonist. Neuropsychopharmacology 2001; 41: 965-975
3 Field M, Cox P, Stott E et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006; 103: 17537-17542
4 Taylor C. The biology and pharmacology of calcium channel alpha2-delta proteins. Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting. Sheraton New Orleans Hotel, New Orleans, LA November 10, 2003. CNS Drug Rev 2004; 10: 183-188
5 Errante L, Petroff O. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 2003; 12: 300-306
6 Cunningham M, Woodhall G, Thompson S et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004; 20: 1566-1576
7 Dooley D, Donovan C, Pugsley T. Stimulus-dependent modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000; 295: 1086-1093
8 Maneuf Y, Hughes J, McKnight A. Gabapentin inhibits the substance P-facilitated K+-evoked release of [3H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001; 93: 191-196
9 Chizh B, Gohring M, Troster A et al. Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers. Br J Anaesth 2007; 98: 246-254
10 Chen S, Xu Z, Pan H. Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. Anesthesiology 2001; 95: 1473-1479
11 Lyrica (pregablin) capsules [prescribing information]. New York, NY: Pfizer, Inc; Revised 06/2011
12 Brodie M, Wilson E, Wesche D et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005; 46: 1407-1413
13 Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 246-255
14 Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical pratice. Epilepsia 2004; 45 (Suppl. 06) 13-18
15 Tassone D, Boyce E, Guyer J et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007; 29: 26-48
16 Dogan S, Ozberk S, Yurci A. Pregabalin-induced hetatotoxicity. Eur J Gastroenterol Hepatol 2011; 23: 628
17 Sendra J, Junyent T, Pellicer M. Pregabalin-induced hepatotoxicity. Ann Pharmacother 2011; 45: e32
18 Schönfeldt-Lecuona C, Wolf R, Osterfeld N et al. Pregabalin in the treatment of schizophrenic anxiety. Pharmacopsychiatry 2008; 41: 1-2
19 Englisch S, Esser A, Enning F et al. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 2010; 30: 437-440
20 Naranjo C, Busto U, Sellers E et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245
21 Englisch S, Alm B, Meyer-Lindenberg A et al. Pregabalin-associated increase of clozapine serum levels. J Clin Psychopharmacol 2012; 32: 127
22 Prior T, Baker G. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28: 99-112